Status:

COMPLETED

Identification of New Diagnostic Protein Markers for Colorectal Cancer

Lead Sponsor:

CHU de Reims

Conditions:

Colorectal Cancer

Eligibility:

All Genders

18+ years

Brief Summary

The search for biochemical markers in patient's blood for non-invasive colorectal cancer diagnostic has not yielded satisfactory results to date. The search for blood in the stool by enzymatic techniq...

Detailed Description

In terms of frequency, colorectal cancer is the third most common cancer diagnosed in men and the second in women. Screening for colon and rectal cancer is based on the search for blood in the stool. ...

Eligibility Criteria

Inclusion

  • Immunoassay for stool positive blood test or family screening
  • Patients seen in consultation for a colonoscopy
  • Patient who gave their consent for the study (signed consent form)
  • Patient affiliated to a health insurance plan

Exclusion

  • History of other cancers (except for cervical cancer or basal cell carcinoma treated for curative purposes)
  • Patient under chemotherapy
  • Patients with a known familial mutation (APC, MSI, MYH)
  • Patients protected by law

Key Trial Info

Start Date :

January 7 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 7 2022

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT04394572

Start Date

January 7 2021

End Date

October 7 2022

Last Update

October 10 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Chu Reims

Reims, France, 51092

Identification of New Diagnostic Protein Markers for Colorectal Cancer | DecenTrialz